Tumour necrosis factor antagonists

Bibliography

• LARSEN GL, HENSEN PM: Mediators of inflammation. Ann. Rev. Immunol. (1982) 1:335–359.
   Web of Science ®Google Scholar
• FELDMANN M, BRENNAN FM, MAINI RN: Role of cytokines in rheumatoid arthritis. Ann. Rev. Immunol. (1996) 14:397–440.
   PubMed Web of Science ®Google Scholar
• ••An excellent review of the role of cytokines in RA with an emphasis on TNF.
   Google Scholar
• DAVIES P, BAILEY PJ, GOLDENBERG MM, et al The role of arachidonic acid oxygenation products in pain and inflammation. Ann. Rev. Immunol. (1983) 2:335–357.
   Web of Science ®Google Scholar
• HEUMANN D, GLAUSER MP: Anticytokine strategies for the treatment of septic shock: relevance of animal models. Curr. Top. Microbiol. Immunol. (1996) 216:299–311.
   PubMed Web of Science ®Google Scholar
• PRASHKER MJ, MEENAN RF: The total cost of drug therapy in rheumatoid arthritis. Arthritis Rheum. (1995) 38:318–325.
   PubMed Web of Science ®Google Scholar
• LANES SF, LANZA LL, RADENSKY PW, et al Resource utilization and cost of care for rheumatoid arthritis and osteoarthritis in a managed care setting: the importance of drug and surgery costs. Arthritis Rheum. (1997) 40:1475–1481.
   PubMed Web of Science ®Google Scholar
• OLD LJ: Tumor necrosis factor (TNF). Science (1985) 230:630–632.
   PubMed Web of Science ®Google Scholar
• VASSALLI P: The pathophysiology of tumor necrosis factor. Ann. Rev. Immunol. (1992) 10:411–452.
   PubMed Web of Science ®Google Scholar
• •A review of the biology of TNF.
   Google Scholar
• BRENNAN FM, MAINI RN, FELDMANN M: TNF-alpha a pivotal role in rheumatoid arthritis Br. J. Rheumatol. (1992) 31:293–298.
   PubMedGoogle Scholar
• BEUTLER B, CERAMI A: Tumor necrosis, cachexia, shock and inflammation: a common mediator. Ann. Rev. Biochem. (1990) 57:505–518.
   Web of Science ®Google Scholar
• DI GIOVINE FS, NUKI G, DUFF GW: Tumor necrosis factor in synovial exudates. Ann. Rheum. Dis. (1988) 47:768–772.
   PubMed Web of Science ®Google Scholar
• •An early paper describing the presence of TNF in synovial fluids of patients with RA.
   Google Scholar
• BUCHAN G, BARRETT K, TURNER M, et al Interleukin-1 and tumor necrosis factor mRNA expression in rheumatoid arthritis: prolonged production of IL- lalpha. Clin. Exp. Immunol. (1988) 73:449–455.
   PubMed Web of Science ®Google Scholar
• BRENNAN FM, CHANTRY D, JACKSON A, et al Inhibitory effects of anti-TNF antibodies on synovial cell interleukin-1 production in rheumatoid arthritis. Lancet (1989) 2:244–247.
   PubMed Web of Science ®Google Scholar
• ••An important paper describing the in vitro inhibitory effect of anti-TNF antibodies oncytokine production by rheumatoid synovial cells.
   Google Scholar
• WILLIAMS RO, GHRAYAB J, FELDMANN M, et al Successful therapy of collagen-induced arthritis with TNF-receptor Ig fusion in combination with anti-CD4. Immunology (1995) 84:433–439.
   PubMed Web of Science ®Google Scholar
• RUDDLE NH, BERGMAN CM, MCGRATH KM, et al An antibody to lymphotoxin and tumor necrosis factor prevents the transfer of experimental allergic encephalomyelitis. J. Exp. Med. (1990) 172:1193–2000.
   PubMed Web of Science ®Google Scholar
• LESSLAUER W, TABUCHI H, GENTZ R, et al Recombinant soluble TNF receptor rsTNFr proteins inhibit LPS-induced lethality in mice. Cytokine (1991) 3:497–500.
   Google Scholar
• VAN ZEE KJ, MOLDAWER LL, OLDENBURGH HAS, et al Protection against lethal Escherichia coli bacteraemia in baboons (Papio anubis) by pretreatment with 55 kDa TNF receptor (CD 120a)-Ig fusion protein, Ro 45-2081. J. Immunol. (1996) 156:2221–2230.
   PubMed Web of Science ®Google Scholar
• LESSLAUER W, TABUCHI H, GENTZ R, et al Recombinant soluble tumor necrosis factor receptor proteins protect mice from lipopolysaccharide-induced lethality. Eur. J. Immunol. (1991) 21:2883–2886.
   PubMed Web of Science ®Google Scholar
• KNIGHT DM, TRINH H, LE J, et al Construction and initial characterization of a mouse human chimeric anti-TNF antibody. Mo/. Immunol. (1993) 30:1443–1453.
   PubMed Web of Science ®Google Scholar
• •Describes the construction of infliximab.
   Google Scholar
• SCALLON BJ, MOORE MA, TRIN H, et al Chimeric anti-TNF alpha monoclonal antibody cA2 binds recombinant transmembrane TNF-alpha and activates immune effector functions. Cytokine (1995) 7:251–259.
   PubMed Web of Science ®Google Scholar
• ELLIOT MJ, MAINI RN, FELDMANN M, et al Randomized double blind comparison of chimeric monoclonal antibody to tumor necrosis factor alpha (cA2) versus placebo in rheumatoid arthritis. Lancet (1994) 344:1105–1110.
   PubMed Web of Science ®Google Scholar
• •The first description of anti-TNF therapy in humans.
   Google Scholar
• ELLIOT MJ, MAINI RN, FELDMANN M, et al Treatment of rheumatoid arthritis with chimeric monoclonal antibody to TNF alpha. Arthritis Rheum. (1993) 36:1681–1690.
   PubMed Web of Science ®Google Scholar
• VAN DULLEMAN HM, VAN DE VENTERS J, HOMMES DW et al Treatment Of Crohn's disease with anti-tumor necrosis factor chimeric monoclonal antibody (cA2). Gastroenterology (1995) 109:129–135.
   PubMed Web of Science ®Google Scholar
• •A description of the use of infliximab in Crohn's disease.
   Google Scholar
• MOOSMEYER D, WAJANT H, GERLACH E, et al Characterization of different soluble TNF receptor (TNFR 80) derivatives: positive influence of the intracellular domain on receptor/ligand interaction and TNF neutralization capacity. J. Interferon Cytokine Res. (1996) 16:471–477.
   PubMed Web of Science ®Google Scholar
• MORELAND LW, BAUMGARTNER SW, SCHIFF MH, et al Treatment of rheumatoid arthritis with a recombinant tumor necrosis factor receptor (p75)-Fc fusion protein. New Engl. J. Med. (1997) 337:141–147.
   PubMed Web of Science ®Google Scholar
• ••A detailed description of the use of etanercept in RA.
   Google Scholar
• FISCHER CJJR, AGOSTI JM, OPAL SM, et al Treatment of septic shock with the tumor necrosis factor receptor Fc fusion protein. The soluble TNF receptor sepsis study group. New Engl. J. Med. (1996) 334:1697–1702.
   PubMed Web of Science ®Google Scholar
• ABRAHAM E, ANZUET A, GUTIERREZ G, et al Double-blind randomized controlled trial of monoclonal antibody to human tumor necrosis factor in treatment of septic shock. J. Am. Med. Assoc. (1998) 351:929–933.
   Google Scholar
• SAMPAIO EP, SARNO EN, GALILLY R, et al Thalidomide selectively inhibits tumor necrosis factor alpha production by stimulated human monocytes. J. Exp. Med. (1991) 173:699–703.
   PubMed Web of Science ®Google Scholar
• GANTNER F, GOETZ C, GEKELER V, et al Phosphodiesterase profile of human B lymphocytes from normal and atopic donors and the effects of PDE inhibition on B cell proliferation. Br. J. Pharmacol. (1998) 123:1031–1038.
   PubMed Web of Science ®Google Scholar
• GRETEN TF, EIGLER A, SINHA B, et al The specific Type IV phosphodiesterase inhibitor rolipram differentially regulates the proinflammatory mediators TNF-alpha and nitric oxide. mt. J. Immunopharmacol. (1995) 17:605–610.
   PubMed Web of Science ®Google Scholar
• STANCOVSKI I, BALTIMORE D: NFid3 Activation: the IkB kinase revealed Cell (1997) 91:299–302.
   PubMed Web of Science ®Google Scholar
• •A review describing current understanding of TNF signal transduction.
   Google Scholar